ADMA Biologics, Inc. (ADMA)Director bought ~$110K
Steve Elms, Director at ADMA Biologics, Inc., bought ~$110K of ADMA Biologics, Inc. shares.
- ~$110K
- Approx. value · 7,000 sh @ $15.67
- 2.04M
- Holds after · shares reported
- Traded
- Mar 5, 2026
- Filed
- Mar 9, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 12, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Feb 17, 2026Insider · 1 personInsiders: 2 sales (~$338K)
- Feb 20, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On February 20, 2026, Brad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”).”
- Mar 5, 2026 · this disclosureInsider · First insider buy since Aug 2023Director purchased ~$110K of ADMA shares in the open market
What came next
- Mar 6, 2026InsiderDirector purchased ~$108K of ADMA shares in the open market
- Mar 9, 2026InsiderOfficer sold ~$158K of ADMA shares in the open market
- Mar 16, 2026Insider · 1 personInsiders: 2 sales (~$318K)
- May 6, 2026Company filing · Form 8-K · ResultsReported its results
- May 11, 2026Insider · First buy since 2023Director purchased ~$100K of ADMA shares in the open market
- May 12, 2026InsiderDirector purchased ~$100K of ADMA shares in the open market
- May 27, 2026InsiderDirector purchased ~$51K of ADMA shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for ADMA Biologics, Inc.
For ADMA Biologics, Inc., OQRO holds 4 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ADMA page.
Other recent filings by Steve Elms, Director
- SEC Form 4 at ADMA Biologics, Inc. (ADMA)Mar 9, 2026
- SEC Form 4 at ADMA Biologics, Inc. (ADMA)Jun 17, 2025
- SEC Form 4 at ADMA Biologics, Inc. (ADMA)Jun 17, 2025
- SEC Form 4 at ADMA Biologics, Inc. (ADMA)Jun 17, 2025
- SEC Form 4 at Marker Therapeutics (MRKR)Dec 26, 2024
The full history of Steve Elms, Director is on the profile page.
How this filing works
Other disclosures at ADMA Biologics, Inc.
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 29, 2026
- SEC Form 4May 28, 2026
Everything OQRO holds on this company is on its ADMA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
